Clinical Trials: Ovarian Cancer

Phase I Radioimmunotherapy with Non-Myeloablative Doses of ⁹⁰Yttrium-Labeled Humanized MN-14 in Advanced Ovarian Cancer

This is a non-randomized, single arm, Phase I/II trial study to administer Yttrium-90 radioisotope-labeled, humanized anti-carcinoembryonic antigen (CEA) antibody MN-14 to advanced ovarian cancer patients who are resistant to other forms of treatment or who have recurrent disease. The dose-escalation study is designed to evaluate the safety, tolerance, maximum tolerated dose (MTD), and potential anti-tumor effects of the test agent.

Who is eligible for this study?

1. Patients must have a histologic or cytologic diagnosis of epithelial ovarian cancer with immunohistologic evidence of CEA target antigen expression.
2. Patients must have failed one regimen of standard chemotherapy.
3. Patients must have adequate blood cell counts and adequate liver, kidney, heart and lung functions.
4. For further information as to the inclusion/exclusion criteria contact Clare Machado, MD (973)-844-7113 or email to: cmachado@gscancer.org